Xeris Biopharma Holdings, Inc.'s revenue has grown 36% a year over three years, and grown 59% a year over five. Revenue growth, 3-year annual rate: +36% (Drug Manufacturers - Specialty & Generic median +12%). Revenue growth, 5-year rate: +59%, growth has slowed since the five-year average. Years of annual history on file: 6, FY2020 to FY2025, as filed.

XERSXeris Biopharma Holdings, Inc.

Healthcare

$10.18+11% 1Y

$10.18

$5.2952 weeks$11.13

Is it growing?

Good

Growing: revenue growing +36% year on year and operating margin widening (+15.9 points).

2 good, 1 without data

Revenue trend+36% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction+15.9 points operating

Trailing-twelve-month operating margin, 10.9% now against -5.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is XERS growing?

Xeris Biopharma Holdings, Inc.'s revenue has grown 36% a year over three years, and grown 59% a year over five.

+36%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +59%
Revenue growth, 5-year rate · +36% over three · growth has slowed since the five-year average
Years of annual history on file: 6
Years of annual history on file · FY2020 to FY2025, as filed

Details›